Navigation Links
Mild HIV type slows development of AIDS and makes new preventive treatments possible

A new study from Lund University in Sweden has opened the way for new approaches to slowing the development of AIDS in HIV-1-infected patients. It is hoped that this could lead to better treatment methods and preventive measures to combat HIV and AIDS.

The findings have just been published in the distinguished scientific journal New England Journal of Medicine.

The most common type of the virus that causes AIDS HIV-1 is less aggressive when it infects a person already carrying the milder HIV-2. The study looked at how the disease developed in those who had been infected with HIV-1 and those who were infected with both HIV-1 and HIV-2.

"The moderating effect of HIV-2 was extremely strong. The time it took to develop AIDS was around 50 per cent longer for those infected with both strains than for those only carrying the HIV-1 virus. The unusually large difference makes me, as a researcher, very optimistic that it will be possible to identify new and significant approaches that can be taken to combating the development of AIDS", says Joakim Esbjrnsson, a virologist at Lund University.

"The unique thing about our study, which has been carried out over 20 years, is that we have been able to follow healthy individuals from when they were infected with HIV-1 only or both HIV-1 and HIV-2 through the entire course of the disease, and to make comparisons of how the infection has developed over time", says Hans Norrgren, doctor in infectious diseases and researcher at Lund University and Skne University Hospital.

An observation that was linked to an early stage of HIV infection was a difference in the genetic diversity of the HIV. It is well-known that different strains of HIV co-exist during the course of the infection and that the genetic difference between them increases the closer to AIDS the infection comes. This genetic difference was lower early on in the disease among people with a dual infection than among those with only HIV-1 infection, which gave them a better starting point from which the development of AIDS was delayed.

The researchers have also studied the levels of CD4+ T cells helper cells with a key role in the immune system that are attacked and destroyed by the HIV virus. Patients with dual infection were also seen to be at an advantage in this. They had a higher number of CD4+ T cells throughout the period of infection. It took longer to reach critically low levels of CD4+ T cells, and thus also longer before the infection developed into AIDS.

"Our results suggest that HIV-2 can activate cellular reactions which naturally check the development of AIDS. If we can map these, I think we can also uncover entirely new mechanisms that are key to the slower development of the disease. In the long run, this could lead to better preventive measures and treatments", says Patrik Medstrand, Professor of Virology at Lund University.

Behind the findings lies a unique 20-year follow-up of 4 700 people in Guinea-Bissau in West Africa.

"Our work is the result of many people's work over many years, in particular the staff of the National Public Health Laboratory in Guinea-Bissau and the police health station in the capital Bissau, who have carried out the practical work of examining the study participants, taking samples and conducting laboratory analyses", says Fredrik Mnsson, a doctor in infectious diseases in Malm and one of the researchers behind the study.


Contact: Joakim Esbjornsson
Lund University

Related medicine news :

1. Oxygen Therapy Slows Type 1 Diabetes in Mice, Study Says
2. Infection With 2 HIV Strains Slows Disease Progression
3. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
4. Kudos for 3 NJIT Enterprise Development Center high-tech companies
5. 2 repressor genes identified as essential for placental development
6. Louisiana Tech University professor earns NSF Early Career Development grant
7. Advanced genetic screening method may speed vaccine development
8. New biospecimens management system in development
9. Developmental Woes Common in Siblings of Children With Autism
10. Mutations impair childhood growth and development by disrupting organization of chromosome pairs
11. Penn and Cornell researchers spearhead the development of new guidelines for veterinary CPR
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... According to Los ... people to overeat are not necessarily caused by real hunger, but instead by ... needs food. He notes that, while many patients are aware that weight loss surgery ...
(Date:11/30/2015)... ... November 30, 2015 , ... A record crowd gathered at the ... organized by the Baruch S. Blumberg Institute. , The institute, which is the research ... science and biotechnology leaders for the conference, which focused on ways companies can work ...
(Date:11/30/2015)... ... November 30, 2015 , ... A novel class of antimicrobials ... effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial ... small molecule analogs that target the functions of SecA, a central part of ...
(Date:11/30/2015)... NJ (PRWEB) , ... November 30, 2015 , ... ... top choice for innovative, patient centered orthopedic care. Led by John Vitolo, ... your injury or chronic condition, the team at Advocare Orthopedic & Sports Medicine ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... specializes in general dentistry out of Glen Ridge, NJ. He has both ... to achieve optimal mastication. He is also an expert in cosmetic dentistry. ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 30, 2015 Diplomat Pharmacy, Inc. (NYSE: ... the Detroit Free Press as a Top Workplace , ... to work for in 2015. ... 100 winners annually, based on employee surveys rating company leadership, ... Workplaces are based solely on employee feedback. The survey is ...
(Date:11/30/2015)... , Nov. 30, 2015  IBA Molecular North America, ... distribution of radiopharmaceuticals, announced that as of January 1, ... (Zevacor Pharma). The decision to rebrand the company reflects ... as well as its close relationship with Zevacor Molecular.  ... Health and Science (IHS). Peter Burke ...
(Date:11/30/2015)... 30, 2015 Baxalta Incorporated (NYSE: ... dedicated to delivering transformative therapies to patients ... today announced the launch and first shipments ... extended circulating half-life recombinant factor VIII (rFVIII) ... ADVATE [Antihemophilic Factor (Recombinant)]. The treatment was ...
Breaking Medicine Technology: